Global Nuclear Medicine/Radiopharmaceuticals
Market Report
2025
Nuclear Medicine/Radiopharmaceuticals Market Report 2025 (Global Edition)
Delivery Includes:- Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
The base year for the calculation is 2024 and 2021 to 2024 will be historical period. The year 2025 will be estimated one while the forecasted data will be from year 2025 to 2033. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
| Share your contact details to receive free updated sample copy/pages of the recently published edition of Nuclear Medicine/Radiopharmaceuticals Market Report 2024.
Global Nuclear Medicine/Radiopharmaceuticals Market Report 2024 Market Size Split by Product type (Diagnostic Products, Therapeutic Products), by Application (Cardiology, Neurology, Oncology, Thyroid,...
-
The global Nuclear Medicine & Radiopharmaceuticals market will expand significantly by xx% CAGR between 2024 and 2031.
-
The demand for Diagnostic Products is rising in the global Nuclear Medicine & Radiopharmaceuticals market.
-
The demand for the Oncology segment is rising in the global Nuclear Medicine & Radiopharmaceuticals market.
-
The demand for the Hospitals & Clinics segment is rising in the global Nuclear Medicine & Radiopharmaceuticals market.
-
North America region will continue to lead, as dominating region and highest compound annual growth rate in the forecast year 2024 to 2031.
| 2019 | 2024 | 2025 | 2032 | 2033 | CAGR | |
|---|---|---|---|---|---|---|
| Global Market Size | 121212 | 121212 | 121212 | 121212 | 121212 | 121212 |
| Country Market Size | 121212 | 121212 | 121212 | 121212 | 121212 | 121212 |
| North Americ Market Size | 121212 | 121212 | 121212 | 121212 | 121212 | 121212 |
| Europe Market Size | 121212 | 121212 | 121212 | 121212 | 121212 | 121212 |
| Asia Pacific Market Size | 121212 | 121212 | 121212 | 121212 | 121212 | 121212 |
| South America Market Size | 121212 | 121212 | 121212 | 121212 | 121212 | 121212 |
| Middle East and Africa Market Size | 121212 | 121212 | 121212 | 121212 | 121212 | 121212 |
| Base Year | 2024 |
| Historical Data Time Period | 2021-2024 |
| Forecast Period | 2025-2033 |
| Market Split by Product type |
|
| Market Split by Application |
|
| Market Split by End-use |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Report scope is customizable as we have a huge database of Nuclear Medicine/Radiopharmaceuticals industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Nuclear Medicine/Radiopharmaceuticals Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Nuclear Medicine/Radiopharmaceuticals Market Report Description
Introduction Nuclear Medicine & Radiopharmaceuticals market
Radioactive materials are used in the diagnosis and treatment of illnesses in the medical profession known as nuclear medicine. Nuclear imaging captures radiation released from within the body, as opposed to traditional radiography, which records radiation passed through the body from external sources such as X-ray machines. Nuclear medicine scans are physiological imaging modalities because they focus on the function of organs and tissues rather than their architecture. Small quantities of radioactive material, a specialized camera, and a computer are used in nuclear medicine imaging to provide photographs of the interior of the body. This makes it possible to diagnose a variety of malignancies, cardiac problems, neurological, gastrointestinal, and endocrine diseases, among other illnesses. Because nuclear medicine scans capture molecular activity within the body, they can detect disease in its early stages, when it may be treated most effectively. The radiopharmaceuticals market is experiencing significant growth due to innovation and advanced technologies. Novartis' FDA approval for Pluvicto production in April 2023 is a significant milestone in the market. Leading players are also conducting M&As to expand services, access new technologies, and consolidate in the rapidly growing market. Regulatory scrutiny is increasing, with Title 21 from the Code of Federal Regulations governing radiopharmaceuticals in the U.S., Part 315 & Part 361, and the Nuclear Regulatory Commission (NRC) in 37 states. The Center for Devices and Radiology Health (CDRH) and the FDA Modernization Act of 1997 also regulate radiopharmaceuticals. Although radiopharmaceutical methods are more accurate than traditional methods, the higher price increases the risk of using substitute products. The threat of substitution is expected to be moderate during the forecast period.
Nuclear Medicine/Radiopharmaceuticals Market Size
Current scenario of the Nuclear Medicine & Radiopharmaceuticals market
Key opportunity in the Nuclear Medicine & Radiopharmaceuticals market
- Increasing technological advancement acts as an opportunity for the Nuclear Medicine & Radiopharmaceuticals market
The development of nuclear medicine therapies is a continuing priority for the firms in this sector. The demand for this therapy option is being driven worldwide by its superior therapeutic results over other medicines. Furthermore, it is projected that the need for market treatments would be driven in nations with a high cancer burden by variables such as the advancement of therapeutic applications, and results in the treatment of cancer, and other ailments.
For example,
Curium received a Study May Proceed letter from the U.S. FDA in October 2021, allowing it to start its Phase-III study with its investigational medication, lutetium Lu 177 PSMA I&T. This radiopharmaceutical is intended for therapeutic purposes and binds to the PSMA protein, which is specific to the prostate.
For example,
FDA Therapy designation for experimental 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) was granted to Advanced Accelerator Applications in June 2021.
Source (https://www.adacap.com/novartis-receives-fda-breakthrough-therapy-designation-for-investigational-177lu-psma-617-in-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc/)
In a similar vein, several industry participants are creating novel medicinal items to address a range of illnesses, which is propelling market expansion.
Key drivers of the Nuclear Medicine & Radiopharmaceuticals market
-
The growing requirement for Nuclear Imaging Modalities drives the Nuclear Medicine & Radiopharmaceuticals market
Growing knowledge of the possible benefits of prompt and early diagnosis, as well as the beneficial effects this has on the management and treatment of chronic illnesses, is one of the key factors propelling the expansion of the worldwide market. Developments in PET/PET-CT, a kind of nuclear imaging technology, have made it possible to use this modality not just for cancer diagnosis but also for cardiology, neurology, and infections. These technical developments have led to a significant rise in the number of PET and SPECT operations.
For example, the OECD reports that the number of PET operations performed in the United States climbed to 2,220,300 in 2020 from 2,200,800 in 2019.
Source (https://stats.oecd.org/fileview2.aspx?IDFile=7a032f96-afc1-4e16-9fe0-d58fa2bbe944)
The growing use of PET scanners was the cause of the rise in procedure volume. Furthermore, advancements like the creation of detectors based on cadmium zinc telluride (CZT), which enables the simultaneous observation of physiological and anatomical structures, are anticipated to propel the use of SPECT-CT systems. The global market's growth is primarily driven by the increasing recognition of the benefits of early and timely diagnosis in managing and treating chronic illnesses.
- Growing requirement of Diagnostic and Therapeutic Products drives the Nuclear Medicine & Radiopharmaceuticals market
The significant emphasis of various industry players to offer new goods in this market is one of the key motivating factors. Strong pipelines for diagnostic goods have been developed, and the growing need for nuclear imaging has prompted new product introductions. Moreover, a big patient population with chronic illnesses encourages producers to introduce new goods into the radiopharmaceutical industry.
For example, GE Healthcare unveiled StarGuide, a nuclear medicine system, in March 2021 to enhance patient outcomes in cancer, neurology, cardiology, and other medical disciplines.
Source (https://www.gehealthcare.dk/about/newsroom/press-releases/ge-healthcare-introduces-starguide-a-new-nuclear-medicine-system-to-help-advance)
In addition, several significant industry giants have partnered and signed agreements to develop and introduce diagnostic tools into the market.
For example, in August 2021, Cardinal Health and IRE-ELiT S.A., a business that specializes in the development of radiopharmaceuticals, signed a distribution deal.
As the need for Positron Emission Tomography (PET) imaging grows in the United States, they are increasing patient access to new products. Shortly, it is also anticipated that growing government financing for nuclear medicine research and development will propel market expansion.
Key restraints of the Nuclear Medicine & Radiopharmaceuticals market
- Growing alternatives for CT and MRI Diagnosis hampers market growth of the Nuclear Medicine & Radiopharmaceuticals market
The worldwide availability of alternative medical imaging modalities, such as CT and MRI scanners, has limited the deployment of nuclear imaging equipment. The exorbitant cost of the technology and its technique, together with an unfavorable reimbursement environment, make nuclear imaging technologies less desirable than MRI and CT scanners. For example, the fact that Medicare does not compensate for all PET medications places growth constraints on PET radiopharmaceuticals. Additionally, in the Medicare hospital outpatient environment in the United States, they are not paid for independently from the treatment. Furthermore, because there are so many CT and MRI scans conducted each year, there is a danger to the expansion of PET-CT procedure volume. For example, the OECD reports that in 2021, Japan was first in terms of the total number of CT and MRI scanners per person, whereas PET scanners were less common. Therefore, it is anticipated that these obstacles to diagnostic radiopharmaceuticals' reimbursement and procedure numbers will restrain market expansion throughout the projection period.
How did COVID-19 impact the Nuclear Medicine & Radiopharmaceuticals market?
In 2020, the market was adversely affected by the COVID-19 epidemic. The market's growth in 2020 was hindered by factors including a shortage of workers and personnel, the possibility of COVID-19 spreading, and the fall in imaging techniques like PET-CT and SPECT scans. The breakdown of supply networks, logistical difficulties, and the adoption of safety precautions—which the centers find difficult to maintain—can all be blamed for the decline in processes. For example, a mean 45.0% decrease in therapy was reported in April 2020, based on a study published in the Journal of Nuclear Medicine. The centers reported the average reduction in radioiodine therapy for benign illnesses and thyroid cancer to be 63% and 47%, respectively.
The primary obstacles to the supply of goods to hospitals were air travel restrictions, complete and partial lockdowns in the majority of nations, and the transit of radionuclides. However, when patient numbers began to rise in 2021 as a result of the ease with which rules were enforced by governments throughout the globe, industry participants saw sluggish income growth. For example, Jubilant Pharmova Limited's income from radiopharmaceuticals increased slowly by 10.9% between 2020 and 2021, from USD 243.6 million to USD 370.1 million. In contrast, the income from radiopharmaceuticals increased rapidly in 2022, rising from USD 270.1 million in 2021 to USD 324.6 million in 2022, a 20.2% increase. Because of the strong demand, the start of services had a favorable effect on the market in 2021 and 2022.
We have various report editions of Nuclear Medicine/Radiopharmaceuticals Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Competitive landscape - Nuclear Medicine & Radiopharmaceuticals market
Nuclear medicine uses radioactive materials to diagnose and treat illnesses, using imaging to capture radiation released from the body. This method focuses on organ and tissue function rather than architecture, allowing for early disease detection and effective treatment. The radiopharmaceuticals market is growing due to innovation and advanced technologies, with Novartis' FDA approval for Pluvicto production in April 2023 being a significant milestone. Leading players are conducting M&As to expand services and access new technologies. Regulatory scrutiny is increasing, with Title 21 governing radiopharmaceuticals in the U.S., Part 315 & Part 361, and the Nuclear Regulatory Commission in 37 states. The Center for Devices and Radiology Health (CDRH) and the FDA Modernization Act of 1997 also regulate radiopharmaceuticals. Several market players, including Cardinal Health, Advanced Accelerator Applications (Novartis AG), Bayer AG, GE Healthcare, Curium, and Jubilant Pharmova Limited, hold around 60% of the global market. They focus on strategies such as new product launches, acquisitions, mergers, and continuous R&D, resulting in strong regulatory approvals.
Top Companies Market Share in Nuclear Medicine/Radiopharmaceuticals Industry: (In no particular order of Rank)
- GE Healthcare
- Jubilant Life Sciences Ltd
- Nordion (Canada)
- Inc.
- Bracco Imaging S.P.A
- The Institute for radioelements (IRE)
- NTP Radioisotopes SOC Ltd.
- The Australian Nuclear Science and Technology Organization
- Eczacıbaşı-Monrol
- Lantheus Medical Imaging
- Inc
- Eckert & Ziegler
- Mallinckrodt
- Cardinal Health
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Which region dominates the market in 2023, and which region is expanding at the fastest CAGR?
In the Nuclear Medicine & Radiopharmaceuticals Market, North America has established itself as the market leader with a significant market share. North America dominated the market in 2023 with a revenue share of xx%; throughout the forecast period, it is anticipated to increase considerably. The region's substantial market share may be attributed to a variety of reasons, including a robust healthcare infrastructure, a high number of nuclear medicine operations, and increased investment in research and development. For instance, Boston, Massachusetts-based Eckert & Ziegler announced intentions to build a cGMP facility for the contract production of radiopharmaceuticals in January 2021. By creating commercial- and late-stage radioisotopes utilized in nuclear medicine, the factory can help fulfill the expanding market demand for radionuclides. The Nuclear Medicine & Radiopharmaceuticals market has seen the most substantial growth rate in Asia Pacific. Because of expanding investment in nuclear medicine space and more knowledge of nuclear medicine therapies, the Asia Pacific area is predicted to develop at the quickest rate. Penang Adventist Hospital (PAH), for example, announced in March 2022 the opening of a private nuclear medicine center in the northern portion of Thailand. It is projected that this introduction would benefit the Asian market. However, because these medicines are expensive, people in emerging nations with lesser incomes may not be able to buy them, which might limit market expansion. For example, the cost of Yttrium-90, Lutetium-177, and Iodine-131 therapy in India may be about USD 23,850, USD 5,962, and USD 3,312 correspondingly.
The current report Scope analyzes Nuclear Medicine/Radiopharmaceuticals Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Nuclear Medicine/Radiopharmaceuticals Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Nuclear Medicine/Radiopharmaceuticals Market Analysis
Global Nuclear Medicine/Radiopharmaceuticals Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Nuclear Medicine/Radiopharmaceuticals Industry growth. Nuclear Medicine/Radiopharmaceuticals market has been segmented with the help of its Product type, Application End-use , and others. Nuclear Medicine/Radiopharmaceuticals market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
The diagnostic product segment, which accounted for XX% of the market share in 2023, is largely driven by advanced technologies like SPECT and PET. With 40 million nuclear medicine procedures performed annually, the demand for radioisotopes is increasing by around 5% annually. Technological advancements and a wide range of radiotracers contribute to the market growth. The therapeutic segment is divided into alpha emitters, beta emitters, and brachytherapy. The U.S. FDA approved and granted a breakthrough designation to diffuse alpha-emitter Radiation Therapy (DaRT) for recurrent glioblastoma multiforme (GBM) patients. Radium (Ra-223) is the most widely used alpha emitter in therapeutics. The development of potential radioisotopes like Terbium (Tb-149), Bismuth (Bi-212), and Actinium (Ac-225) is expected to further boost market growth.
Nuclear Medicine/Radiopharmaceuticals Market Share (%) by Product type in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Nuclear Medicine/Radiopharmaceuticals Industry. Request a Free Sample PDF!
Global nuclear medicine is categorized into many markets based on application, including cancer, thyroid, neurology, cardiology, lymphoma, bone metastases, and endocrine tumors. In 2023, the oncology category had a dominant market share. One of the main causes of mortality in the globe is cancer. The increased incidence can be attributed to several factors, including poor diet, harmful behaviors like smoking, and insufficient exercise. Moreover, increased spending on the research and development of innovative nuclear medications for cancer therapy may support the segment's expansion. For example, ITM Isotope Technologies Munich SE started the COMPOSE phase 3 study of 177lu-edotreotide in January 2022 to assess the product's suitability for treating neuroendocrine tumor patients.
Nuclear Medicine/Radiopharmaceuticals Market Share (%) by Application in 2019-2031
2021
2025
2033
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Nuclear Medicine/Radiopharmaceuticals End-use Segment Analysis
In 2023, hospitals dominated the nuclear medicine market due to the high number of procedures conducted in these facilities, leading to a higher demand for diagnostic radiopharmaceuticals. Over 10,000 hospitals worldwide use radioisotopes for diagnostic purposes, with Technetium-99 being the most commonly used. The hospital segment is expected to grow at a CAGR of % during the forecast period. The growth of therapeutic nuclear medicine procedures in hospitals is driven by the recent approval of multiple therapeutic radioisotopes, such as Pluvicto and Lutathera, and the development of Lu 177 PSMA I&T and Lu 177 edotreotide.
- Hospitals & Clinics
- Diagnostic Centres
- Others
Author's Detail
Manjiri KanhereSenior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The Global Nuclear Medicine/Radiopharmaceuticals Market is witnessing significant growth in the near future.
In 2023, the Diagnostic Products segment accounted for noticeable share of global Nuclear Medicine/Radiopharmaceuticals Market and is projected to experience significant growth in the near future.
The Cardiology segment is expected to expand at the significant CAGR retaining position throughout the forecast period.
Some of the key companies GE Healthcare , Nordion (Canada) and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.
Frequently Asked Questions (FAQs)
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Nuclear Medicine/Radiopharmaceuticals Market
For example,
GE Healthcare and NorthStar Medical Radioisotopes, LLC announced in August 2021 that they had reached an exclusive deal to produce and sell iodine-123 (I-123) capsules in the United States. The device will boost GE Healthcare's market presence and aid in diversifying its product line.
For example,
For example, Noria Therapeutics Inc. and PSMA Therapeutics Inc. were acquired by Bayer AG in June 2021. Targeted therapeutic and imaging radiopharmaceuticals are being developed by both radiotherapy businesses. It is anticipated that this acquisition would broaden Bayer's current nuclear medicine cancer offering.
Sources from Pharma & Healthcare Industry
- https://en.wikipedia.org/wiki/American_Society_for_Pharmacy_Law
- https://en.wikipedia.org/wiki/American_Society_of_Consultant_Pharmacists
- https://en.wikipedia.org/wiki/American_Society_of_Health-System_Pharmacists
- https://www.apsm-uk.com/
- https://en.wikipedia.org/wiki/Australasian_College_of_Pharmacy
- https://en.wikipedia.org/wiki/American_Association_of_Colleges_of_Pharmacy
- https://en.wikipedia.org/wiki/American_College_of_Clinical_Pharmacy
- https://en.wikipedia.org/wiki/American_Pharmacists_Association
- https://www.bio.org/
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Association
- https://en.wikipedia.org/wiki/Canadian_Society_of_Hospital_Pharmacists
- https://en.wikipedia.org/wiki/Chinese_Pharmaceutical_Association
- https://en.wikipedia.org/wiki/American_Association_of_Psychiatric_Pharmacists
- https://en.wikipedia.org/wiki/Danish_Association_of_Pharmaconomists
- https://en.wikipedia.org/wiki/EPhEU
- https://www.fda.gov/
- https://www.gmc-uk.org/
- https://www.ifpma.org/
- https://www.fip.org/
- https://en.wikipedia.org/wiki/International_Pharmaceutical_Students%27_Federation
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://en.wikipedia.org/wiki/National_Pharmacy_Association
- https://en.wikipedia.org/wiki/Norwegian_Pharmacy_Association
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Journal#History
- https://en.wikipedia.org/wiki/Pakistan_Pharmacists_Association
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Mauritius
- https://en.wikipedia.org/wiki/Pharmaceutical_Group_of_the_European_Union
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Australia
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_New_Zealand
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Northern_Ireland
- https://en.wikipedia.org/wiki/Professional_Compounding_Centers_of_America
- https://en.wikipedia.org/wiki/Royal_Pharmaceutical_Society
- https://www.aaps.org/home
- https://www.bioindustry.org/
- https://www.controlledreleasesociety.org/
- https://www.efpia.eu/
- https://www.epemed.org/online/www/content/ENG/index.html
- https://icr-global.org/
- https://ispe.org/
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Israel
- https://www.phrma.org/
- https://en.wikipedia.org/wiki/The_Pharmacy_Guild_of_Australia
- https://en.wikipedia.org/wiki/The_Society_of_Hospital_Pharmacists_of_Australia
- https://en.wikipedia.org/wiki/Healthcare_industry
- https://www.pharma-iq.com/business-development/articles/top-50-pharmaceutical-blogs-and-publications
- https://www.pharmatimes.com/news
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967517/
- https://www.cbo.gov/publication/57126
- http://: https://www.who.int/tools/atc-ddd-toolkit/data
- https://www.oecd.org/els/health-systems/health-data.htm
- https://www.bls.gov/ooh/healthcare/home.htm
- https://data.worldbank.org/topic/8
- https://www.statnews.com/about/
- https://www.health.pa.gov/topics/HealthStatistics/Pages/health-statistics.aspx
- https://www.cdc.gov/nchs/index.htm
- https://www.aha.org/statistics/fast-facts-us-hospitals
- https://www.census.gov/library/publications/2021/demo/p60-274.html
- https://www.adb.org/what-we-do/sectors/health/main
Nuclear Medicine/Radiopharmaceuticals Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Product type | Diagnostic Products, Therapeutic Products |
| Application | Cardiology, Neurology, Oncology, Thyroid, Lymphoma, Bone Metastasis, Endocrine Tumour, Others |
| End-use | Hospitals & Clinics, Diagnostic Centres, Others |
| List of Competitors | GE Healthcare, Jubilant Life Sciences Ltd, Nordion (Canada), Inc., Bracco Imaging S.P.A, The Institute for radioelements (IRE), NTP Radioisotopes SOC Ltd., The Australian Nuclear Science and Technology Organization, Eczacıbaşı-Monrol, Lantheus Medical Imaging, Inc, Eckert & Ziegler, Mallinckrodt, Cardinal Health |
This chapter will help you gain GLOBAL Market Analysis of Nuclear Medicine/Radiopharmaceuticals. Further deep in this chapter, you will be able to review Global Nuclear Medicine/Radiopharmaceuticals Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Nuclear Medicine/Radiopharmaceuticals Revenue Market Size, Trend Analysis 2021 - 2033
-
1.2 Global Nuclear Medicine/Radiopharmaceuticals Market Size By Regions 2021 - 2033
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Nuclear Medicine/Radiopharmaceuticals Revenue Market Size By Region
-
-
1.3 Global Nuclear Medicine/Radiopharmaceuticals Market Size By Product type 2021 - 2033
-
1.3.1 Diagnostic Products Market Size
-
1.3.2 Therapeutic Products Market Size
-
-
1.4 Global Nuclear Medicine/Radiopharmaceuticals Market Size By Application 2021 - 2033
-
1.4.1 Cardiology Market Size
-
1.4.2 Neurology Market Size
-
1.4.3 Oncology Market Size
-
1.4.4 Thyroid Market Size
-
1.4.5 Lymphoma Market Size
-
1.4.6 Bone Metastasis Market Size
-
1.4.7 Endocrine Tumour Market Size
-
1.4.8 Others Market Size
-
-
1.5 Global Nuclear Medicine/Radiopharmaceuticals Market Size By End-use 2021 - 2033
-
1.5.1 Hospitals & Clinics Market Size
-
1.5.2 Diagnostic Centres Market Size
-
1.5.3 Others Market Size
-
-
1.6 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.7 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.7.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.7.2 Global Market Revenue Split By Product type
-
1.7.3 Global Market Revenue Split By Application
-
1.7.4 Global Market Revenue Split By End-use
-
1.7.5 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
This chapter will help you gain North America Market Analysis of Nuclear Medicine/Radiopharmaceuticals. Further deep in this chapter, you will be able to review North America Nuclear Medicine/Radiopharmaceuticals Market Split by various segments and Country Split.
Chapter 2 North America Market Analysis
-
2.1 North America Nuclear Medicine/Radiopharmaceuticals Market Size 2021 - 2033
-
2.1.1 North America Nuclear Medicine/Radiopharmaceuticals Market Size By Country 2021 - 2033
-
2.1.2 North America Nuclear Medicine/Radiopharmaceuticals Market Size by Product type 2021 - 2033
-
2.1.2.1 North America Diagnostic Products Market Size
-
2.1.2.2 North America Therapeutic Products Market Size
-
-
2.1.3 North America Nuclear Medicine/Radiopharmaceuticals Market Size by Application 2021 - 2033
-
2.1.3.1 North America Cardiology Market Size
-
2.1.3.2 North America Neurology Market Size
-
2.1.3.3 North America Oncology Market Size
-
2.1.3.4 North America Thyroid Market Size
-
2.1.3.5 North America Lymphoma Market Size
-
2.1.3.6 North America Bone Metastasis Market Size
-
2.1.3.7 North America Endocrine Tumour Market Size
-
2.1.3.8 North America Others Market Size
-
-
2.1.4 North America Nuclear Medicine/Radiopharmaceuticals Market Size by End-use 2021 - 2033
-
2.1.4.1 North America Hospitals & Clinics Market Size
-
2.1.4.2 North America Diagnostic Centres Market Size
-
2.1.4.3 North America Others Market Size
-
-
This chapter will help you gain Europe Market Analysis of Nuclear Medicine/Radiopharmaceuticals. Further deep in this chapter, you will be able to review Europe Nuclear Medicine/Radiopharmaceuticals Market Split by various segments and Country Split.
Chapter 3 Europe Market Analysis
-
3.1 Europe Nuclear Medicine/Radiopharmaceuticals Market Size 2021 - 2033
-
3.1.1 Europe Nuclear Medicine/Radiopharmaceuticals Market Size By Country 2021 - 2033
-
3.1.2 Europe Nuclear Medicine/Radiopharmaceuticals Market Size by Product type 2021 - 2033
-
3.1.2.1 Europe Diagnostic Products Market Size
-
3.1.2.2 Europe Therapeutic Products Market Size
-
-
3.1.3 Europe Nuclear Medicine/Radiopharmaceuticals Market Size by Application 2021 - 2033
-
3.1.3.1 Europe Cardiology Market Size
-
3.1.3.2 Europe Neurology Market Size
-
3.1.3.3 Europe Oncology Market Size
-
3.1.3.4 Europe Thyroid Market Size
-
3.1.3.5 Europe Lymphoma Market Size
-
3.1.3.6 Europe Bone Metastasis Market Size
-
3.1.3.7 Europe Endocrine Tumour Market Size
-
3.1.3.8 Europe Others Market Size
-
-
3.1.4 Europe Nuclear Medicine/Radiopharmaceuticals Market Size by End-use 2021 - 2033
-
3.1.4.1 Europe Hospitals & Clinics Market Size
-
3.1.4.2 Europe Diagnostic Centres Market Size
-
3.1.4.3 Europe Others Market Size
-
-
This chapter will help you gain Asia Pacific Market Analysis of Nuclear Medicine/Radiopharmaceuticals. Further deep in this chapter, you will be able to review Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Split by various segments and Country Split.
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Size 2021 - 2033
-
4.1.1 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Size By Country 2021 - 2033
-
4.1.2 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Size by Product type 2021 - 2033
-
4.1.2.1 Asia Pacific Diagnostic Products Market Size
-
4.1.2.2 Asia Pacific Therapeutic Products Market Size
-
-
4.1.3 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Size by Application 2021 - 2033
-
4.1.3.1 Asia Pacific Cardiology Market Size
-
4.1.3.2 Asia Pacific Neurology Market Size
-
4.1.3.3 Asia Pacific Oncology Market Size
-
4.1.3.4 Asia Pacific Thyroid Market Size
-
4.1.3.5 Asia Pacific Lymphoma Market Size
-
4.1.3.6 Asia Pacific Bone Metastasis Market Size
-
4.1.3.7 Asia Pacific Endocrine Tumour Market Size
-
4.1.3.8 Asia Pacific Others Market Size
-
-
4.1.4 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Size by End-use 2021 - 2033
-
4.1.4.1 Asia Pacific Hospitals & Clinics Market Size
-
4.1.4.2 Asia Pacific Diagnostic Centres Market Size
-
4.1.4.3 Asia Pacific Others Market Size
-
-
This chapter will help you gain South America Market Analysis of Nuclear Medicine/Radiopharmaceuticals. Further deep in this chapter, you will be able to review South America Nuclear Medicine/Radiopharmaceuticals Market Split by various segments and Country Split.
Chapter 5 South America Market Analysis
-
5.1 South America Nuclear Medicine/Radiopharmaceuticals Market Size 2021 - 2033
-
5.1.1 South America Nuclear Medicine/Radiopharmaceuticals Market Size By Country 2021 - 2033
-
5.1.2 South America Nuclear Medicine/Radiopharmaceuticals Market Size by Product type 2021 - 2033
-
5.1.2.1 South America Diagnostic Products Market Size
-
5.1.2.2 South America Therapeutic Products Market Size
-
-
5.1.3 South America Nuclear Medicine/Radiopharmaceuticals Market Size by Application 2021 - 2033
-
5.1.3.1 South America Cardiology Market Size
-
5.1.3.2 South America Neurology Market Size
-
5.1.3.3 South America Oncology Market Size
-
5.1.3.4 South America Thyroid Market Size
-
5.1.3.5 South America Lymphoma Market Size
-
5.1.3.6 South America Bone Metastasis Market Size
-
5.1.3.7 South America Endocrine Tumour Market Size
-
5.1.3.8 South America Others Market Size
-
-
5.1.4 South America Nuclear Medicine/Radiopharmaceuticals Market Size by End-use 2021 - 2033
-
5.1.4.1 South America Hospitals & Clinics Market Size
-
5.1.4.2 South America Diagnostic Centres Market Size
-
5.1.4.3 South America Others Market Size
-
-
This chapter will help you gain Middle East and Africa Market Analysis of Nuclear Medicine/Radiopharmaceuticals. Further deep in this chapter, you will be able to review Middle East and Africa Nuclear Medicine/Radiopharmaceuticals Market Split by various segments and Country Split.
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Nuclear Medicine/Radiopharmaceuticals Market Size 2021 - 2033
-
6.1.1 Middle East and Africa Nuclear Medicine/Radiopharmaceuticals Market Size By Country 2021 - 2033
-
6.1.2 Middle East and Africa Nuclear Medicine/Radiopharmaceuticals Market Size by Product type 2021 - 2033
-
6.1.2.1 Middle East and Africa Diagnostic Products Market Size
-
6.1.2.2 Middle East and Africa Therapeutic Products Market Size
-
-
6.1.3 Middle East and Africa Nuclear Medicine/Radiopharmaceuticals Market Size by Application 2021 - 2033
-
6.1.3.1 Middle East and Africa Cardiology Market Size
-
6.1.3.2 Middle East and Africa Neurology Market Size
-
6.1.3.3 Middle East and Africa Oncology Market Size
-
6.1.3.4 Middle East and Africa Thyroid Market Size
-
6.1.3.5 Middle East and Africa Lymphoma Market Size
-
6.1.3.6 Middle East and Africa Bone Metastasis Market Size
-
6.1.3.7 Middle East and Africa Endocrine Tumour Market Size
-
6.1.3.8 Middle East and Africa Others Market Size
-
-
6.1.4 Middle East and Africa Nuclear Medicine/Radiopharmaceuticals Market Size by End-use 2021 - 2033
-
6.1.4.1 Middle East and Africa Hospitals & Clinics Market Size
-
6.1.4.2 Middle East and Africa Diagnostic Centres Market Size
-
6.1.4.3 Middle East and Africa Others Market Size
-
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Nuclear Medicine/Radiopharmaceuticals Market Size by Product type 2021 - 2033
-
7.1.2 Country 1Nuclear Medicine/Radiopharmaceuticals Market Size by Application 2021 - 2033
-
7.1.3 Country 1Nuclear Medicine/Radiopharmaceuticals Market Size by End-use 2021 - 2033
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
This chapter provides an in-depth analysis of the market share among key competitors of Nuclear Medicine/Radiopharmaceuticals. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Nuclear Medicine/Radiopharmaceuticals Market Revenue and Share by Key Players
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 GE Healthcare
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 Jubilant Life Sciences Ltd
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 Nordion (Canada)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 Bracco Imaging S.P.A
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 The Institute for radioelements (IRE)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 NTP Radioisotopes SOC Ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 The Australian Nuclear Science and Technology Organization
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 Eczacıbaşı-Monrol
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
8.2.10 Lantheus Medical Imaging
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.10.2 Business Overview
-
8.2.10.3 Financials (Subject to data availability)
-
8.2.10.4 Product Types Specification
-
8.2.10.5 Business Strategy
-
8.2.10.6 S.W.O.TAnalysis
-
-
8.2.11 Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.11.2 Business Overview
-
8.2.11.3 Financials (Subject to data availability)
-
8.2.11.4 Product Types Specification
-
8.2.11.5 Business Strategy
-
8.2.11.6 S.W.O.TAnalysis
-
-
8.2.12 Eckert & Ziegler
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.12.2 Business Overview
-
8.2.12.3 Financials (Subject to data availability)
-
8.2.12.4 Product Types Specification
-
8.2.12.5 Business Strategy
-
8.2.12.6 S.W.O.TAnalysis
-
-
8.2.13 Mallinckrodt
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.13.2 Business Overview
-
8.2.13.3 Financials (Subject to data availability)
-
8.2.13.4 Product Types Specification
-
8.2.13.5 Business Strategy
-
8.2.13.6 S.W.O.TAnalysis
-
-
8.2.14 Cardinal Health
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.14.2 Business Overview
-
8.2.14.3 Financials (Subject to data availability)
-
8.2.14.4 Product Types Specification
-
8.2.14.5 Business Strategy
-
8.2.14.6 S.W.O.TAnalysis
-
-
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Restraints
-
9.3 Market Trends
-
9.4 Market Opportunity
-
9.5 Technological Road Map (Subject to Data Availability)
-
9.6 Product Life Cycle (Subject to Data Availability)
-
9.7 Consumer Preference Analysis
-
9.8 Market Attractiveness Analysis
-
9.9 PESTEL Analysis
-
9.9.1 Political Factors
-
9.9.2 Economic Factors
-
9.9.3 Social Factors
-
9.9.4 Technological Factors
-
9.9.5 Legal Factors
-
9.9.6 Environmental Factors
-
-
9.10 Industrial Chain Analysis (Subject to Data Availability)
-
9.10.1 Industry Chain Analysis
-
9.10.2 Manufacturing Cost Analysis
-
9.10.3 Supply Side Analysis
-
9.10.3.1 Raw Material Analysis
-
9.10.3.2 Raw Material Procurement Analysis
-
9.10.3.3 Raw Material Price Trend Analysis
-
-
-
9.11 Porter’s Five Forces Analysis
-
9.11.1 Bargaining Power of Suppliers
-
9.11.2 Bargaining Power of Buyers
-
9.11.3 Threat of New Entrants
-
9.11.4 Threat of Substitutes
-
9.11.5 Degree of Competition
-
-
9.12 Patent Analysis (Subject to Data Availability)
-
9.13 ESG Analysis
Segmentation Product type Analysis 2019 -2031, will provide market size split by Product type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Product type Analysis 2021 - 2033
-
10.1 Diagnostic Products
-
10.1.1 Global Nuclear Medicine/Radiopharmaceuticals Revenue Market Size and Share by Diagnostic Products 2021 - 2033
-
-
10.2 Therapeutic Products
-
10.2.1 Global Nuclear Medicine/Radiopharmaceuticals Revenue Market Size and Share by Therapeutic Products 2021 - 2033
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Application Analysis 2021 - 2033
-
11.1 Cardiology
-
11.1.1 Global Nuclear Medicine/Radiopharmaceuticals Revenue Market Size and Share by Cardiology 2021 - 2033
-
-
11.2 Neurology
-
11.2.1 Global Nuclear Medicine/Radiopharmaceuticals Revenue Market Size and Share by Neurology 2021 - 2033
-
-
11.3 Oncology
-
11.3.1 Global Nuclear Medicine/Radiopharmaceuticals Revenue Market Size and Share by Oncology 2021 - 2033
-
-
11.4 Thyroid
-
11.4.1 Global Nuclear Medicine/Radiopharmaceuticals Revenue Market Size and Share by Thyroid 2021 - 2033
-
-
11.5 Lymphoma
-
11.5.1 Global Nuclear Medicine/Radiopharmaceuticals Revenue Market Size and Share by Lymphoma 2021 - 2033
-
-
11.6 Bone Metastasis
-
11.6.1 Global Nuclear Medicine/Radiopharmaceuticals Revenue Market Size and Share by Bone Metastasis 2021 - 2033
-
-
11.7 Endocrine Tumour
-
11.7.1 Global Nuclear Medicine/Radiopharmaceuticals Revenue Market Size and Share by Endocrine Tumour 2021 - 2033
-
-
11.8 Others
-
11.8.1 Global Nuclear Medicine/Radiopharmaceuticals Revenue Market Size and Share by Others 2021 - 2033
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by End-use Analysis 2021 - 2033
-
12.1 Hospitals & Clinics
-
12.1.1 Global Nuclear Medicine/Radiopharmaceuticals Revenue Market Size and Share by Hospitals & Clinics 2021 - 2033
-
-
12.2 Diagnostic Centres
-
12.2.1 Global Nuclear Medicine/Radiopharmaceuticals Revenue Market Size and Share by Diagnostic Centres 2021 - 2033
-
-
12.3 Others
-
12.3.1 Global Nuclear Medicine/Radiopharmaceuticals Revenue Market Size and Share by Others 2021 - 2033
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Nuclear Medicine/Radiopharmaceuticals market
Chapter 13 Research Findings
-
13.1 Key Takeaways
-
13.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
13.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Research Methodology Implemented by Manjiri Kanhere and Team
- 1.1 Nuclear Medicine/Radiopharmaceuticals Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Nuclear Medicine/Radiopharmaceuticals Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Nuclear Medicine/Radiopharmaceuticals Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Nuclear Medicine/Radiopharmaceuticals Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Nuclear Medicine/Radiopharmaceuticals Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Nuclear Medicine/Radiopharmaceuticals Market
Key Questions Answered By Nuclear Medicine/Radiopharmaceuticals Market Report 2024
| Why Diagnostic Products have a significant impact on Nuclear Medicine/Radiopharmaceuticals market? |
| What are the key factors affecting the Diagnostic Products and Therapeutic Products of Nuclear Medicine/Radiopharmaceuticals Market? |
| What is the CAGR/Growth Rate of Cardiology during the forecast period? |
| By type, which segment accounted for largest share of the global Nuclear Medicine/Radiopharmaceuticals Market? |
| Which region is expected to dominate the global Nuclear Medicine/Radiopharmaceuticals Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
